KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortizatization of Intangibles (2017 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Amortizatization of Intangibles for 9 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 25.11% to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.0 million, a 46.37% increase, with the full-year FY2025 number at $8.0 million, up 46.37% from a year prior.
  • Amortizatization of Intangibles was $6.0 million for Q4 2025 at Supernus Pharmaceuticals, up from $921000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $7.9 million in Q4 2024 to a low of -$2.1 million in Q3 2022.
  • A 5-year average of $814200.0 and a median of $196000.0 in 2022 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: skyrocketed 31511.11% in 2023, then crashed 1320.59% in 2024.
  • Supernus Pharmaceuticals' Amortizatization of Intangibles stood at -$1.3 million in 2021, then skyrocketed by 98.57% to -$18000.0 in 2022, then surged by 31511.11% to $5.7 million in 2023, then skyrocketed by 40.59% to $7.9 million in 2024, then fell by 25.11% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Amortizatization of Intangibles are $6.0 million (Q4 2025), $921000.0 (Q3 2025), and $32000.0 (Q2 2025).